Vanguard Personalized Indexing Management LLC Buys 2,337 Shares of Revvity, Inc. (NYSE:RVTY)

Vanguard Personalized Indexing Management LLC lifted its stake in shares of Revvity, Inc. (NYSE:RVTY) by 21.8% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 13,078 shares of the company’s stock after acquiring an additional 2,337 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Revvity were worth $1,353,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in RVTY. Argent Trust Co boosted its position in Revvity by 12.9% during the second quarter. Argent Trust Co now owns 6,472 shares of the company’s stock worth $679,000 after purchasing an additional 738 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Revvity by 5.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,149,122 shares of the company’s stock worth $120,506,000 after buying an additional 57,656 shares during the period. Keene & Associates Inc. grew its stake in Revvity by 17.5% in the 2nd quarter. Keene & Associates Inc. now owns 4,553 shares of the company’s stock valued at $477,000 after buying an additional 678 shares during the last quarter. Fairfield Financial Advisors LTD bought a new position in Revvity in the 2nd quarter worth $43,000. Finally, Brown Brothers Harriman & Co. lifted its position in Revvity by 24.5% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 2,116 shares of the company’s stock worth $222,000 after acquiring an additional 416 shares during the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Performance

Revvity stock opened at $122.89 on Monday. The firm has a market capitalization of $15.16 billion, a P/E ratio of 101.56, a P/E/G ratio of 2.87 and a beta of 1.05. The stock has a fifty day moving average price of $119.06 and a two-hundred day moving average price of $110.62. Revvity, Inc. has a 52-week low of $79.50 and a 52-week high of $128.15. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.98.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, July 29th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.12 by $0.10. The business had revenue of $691.70 million during the quarter, compared to analysts’ expectations of $690.33 million. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. During the same quarter last year, the company posted $1.21 EPS. As a group, analysts anticipate that Revvity, Inc. will post 4.75 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.23%. Revvity’s dividend payout ratio is 23.14%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Citigroup lifted their price objective on Revvity from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. JPMorgan Chase & Co. upped their price target on Revvity from $105.00 to $120.00 and gave the stock a “neutral” rating in a report on Tuesday, July 30th. Bank of America raised their price objective on shares of Revvity from $118.00 to $127.00 and gave the stock a “neutral” rating in a research note on Tuesday, July 30th. Leerink Partners began coverage on shares of Revvity in a research note on Monday, July 8th. They set an “outperform” rating and a $125.00 target price for the company. Finally, TD Cowen raised their price target on shares of Revvity from $130.00 to $141.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Insider Buying and Selling at Revvity

In other news, insider Joel S. Goldberg sold 3,500 shares of the stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $117.86, for a total transaction of $412,510.00. Following the sale, the insider now owns 33,400 shares in the company, valued at $3,936,524. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.60% of the company’s stock.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.